Instrument Inactif

Autres langues Ibere Pharmaceuticals

Actions

14/11/22	Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
12/08/22	Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
16/05/22	Ibere Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022
31/03/22	Ibere Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021
31/03/22	Ibere Pharmaceuticals Auditor Raises 'Going Concern' Doubt
12/11/21	Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
24/08/21	Certain Class B Ordinary Shares of Ibere Pharmaceuticals are subject to a Lock-Up Agreement Ending on 24-AUG-2021.
16/08/21	Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter Ended June 30, 2021
04/08/21	Ibere Pharmaceuticals : Letter dated August 4, 2021 from Marcum LLP (Form 8-K)
29/05/21	Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report
28/05/21	Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report (Form 8-K)
02/03/21	Ibere Pharmaceuticals announced that it has received $4.835 million in funding
26/02/21	Ibere Pharmaceuticals has completed an IPO in the amount of $120 million.
25/02/21	Ibere Pharmaceuticals announced that it expects to receive $4.835 million in funding
08/02/21	Ibere Pharmaceuticals has filed an IPO in the amount of $100 million.